HK1206367A1 - 中和 的抗體及其用途 - Google Patents

中和 的抗體及其用途

Info

Publication number
HK1206367A1
HK1206367A1 HK15106957.1A HK15106957A HK1206367A1 HK 1206367 A1 HK1206367 A1 HK 1206367A1 HK 15106957 A HK15106957 A HK 15106957A HK 1206367 A1 HK1206367 A1 HK 1206367A1
Authority
HK
Hong Kong
Prior art keywords
pvm
rsvmpv
mpv
antibodies
neutralize rsv
Prior art date
Application number
HK15106957.1A
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed S A filed Critical Humabs Biomed S A
Publication of HK1206367A1 publication Critical patent/HK1206367A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15106957.1A 2012-03-20 2015-07-21 中和 的抗體及其用途 HK1206367A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613197P 2012-03-20 2012-03-20
US201261655310P 2012-06-04 2012-06-04
PCT/IB2013/000627 WO2013140247A1 (en) 2012-03-20 2013-03-14 Antibodies that neutralize rsv, mpv and pvm and uses thereof

Publications (1)

Publication Number Publication Date
HK1206367A1 true HK1206367A1 (zh) 2016-01-08

Family

ID=48471031

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106957.1A HK1206367A1 (zh) 2012-03-20 2015-07-21 中和 的抗體及其用途

Country Status (17)

Country Link
US (4) US9498531B2 (zh)
EP (1) EP2828293B1 (zh)
JP (4) JP6445423B2 (zh)
KR (1) KR102149069B1 (zh)
CN (2) CN107880121B (zh)
AU (1) AU2013237087B2 (zh)
BR (1) BR112014023063A2 (zh)
CA (1) CA2865856C (zh)
DK (1) DK2828293T3 (zh)
EA (1) EA030319B1 (zh)
ES (1) ES2657470T3 (zh)
HK (1) HK1206367A1 (zh)
IL (1) IL234710A (zh)
IN (1) IN2014DN07299A (zh)
NZ (1) NZ630920A (zh)
PL (1) PL2828293T3 (zh)
WO (1) WO2013140247A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2828293T3 (en) 2012-03-20 2018-01-08 Humabs Biomed S A ANTIBODIES NEUTRALIZING RSV, MPV AND PVM AND USE THEREOF
KR20150135231A (ko) 2013-01-28 2015-12-02 에베크 인코포레이티드 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2020160171A1 (en) * 2019-01-29 2020-08-06 Sanford Burnham Prebys Medical Discovery Institute Topically formulated antibody compositions for reducing pathogen transmission and methods of using same
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
BR112023015900A2 (pt) * 2021-02-09 2023-10-17 Humabs Biomed Sa Anticorpos contra vírus sincicial respiratório, metapneumovírus humano e vírus da pneumonia de comundongos e métodos de uso dos mesmos
JP2024507948A (ja) * 2021-02-26 2024-02-21 フレッド ハッチンソン キャンサー センター 呼吸器ウイルス感染症に対する防御抗体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2004092207A2 (en) 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
EP1473037A1 (en) 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP5837820B2 (ja) 2008-10-22 2015-12-24 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ 形質細胞から抗体を産生する方法
AU2010264686A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
EA023179B1 (ru) * 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
MX343298B (es) * 2010-07-09 2016-11-01 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
DK2828293T3 (en) * 2012-03-20 2018-01-08 Humabs Biomed S A ANTIBODIES NEUTRALIZING RSV, MPV AND PVM AND USE THEREOF

Also Published As

Publication number Publication date
CN107880121A (zh) 2018-04-06
KR20140135259A (ko) 2014-11-25
EA201491724A1 (ru) 2015-01-30
EP2828293B1 (en) 2017-10-25
US9498531B2 (en) 2016-11-22
AU2013237087B2 (en) 2017-07-20
US10072071B2 (en) 2018-09-11
JP6445423B2 (ja) 2018-12-26
EA030319B1 (ru) 2018-07-31
KR102149069B1 (ko) 2020-08-28
JP2019076091A (ja) 2019-05-23
ES2657470T3 (es) 2018-03-05
AU2013237087A1 (en) 2014-09-18
US20170121393A1 (en) 2017-05-04
US20190153073A1 (en) 2019-05-23
US20140037648A1 (en) 2014-02-06
NZ630920A (en) 2017-01-27
DK2828293T3 (en) 2018-01-08
BR112014023063A2 (pt) 2017-07-18
CA2865856C (en) 2023-03-14
CN104350069B (zh) 2017-12-01
JP2020182464A (ja) 2020-11-12
US11421020B2 (en) 2022-08-23
JP6722264B2 (ja) 2020-07-15
PL2828293T3 (pl) 2018-03-30
CN104350069A (zh) 2015-02-11
EP2828293A1 (en) 2015-01-28
WO2013140247A1 (en) 2013-09-26
JP2022132244A (ja) 2022-09-07
JP2015514068A (ja) 2015-05-18
IL234710A (en) 2016-12-29
CN107880121B (zh) 2022-02-18
IN2014DN07299A (zh) 2015-04-24
US20210115114A1 (en) 2021-04-22
CA2865856A1 (en) 2013-09-26
JP7069251B2 (ja) 2022-05-17

Similar Documents

Publication Publication Date Title
IL238192A0 (en) Antibodies that recognize alpha-synuclei, preparations containing them and their uses
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
HK1207092A1 (zh) 抗- 抗體及其用途
EP2978640A4 (en) Vehicular occupancy assessment
EP3089994A4 (en) Fabs-in-tandem immunoglobulin and uses thereof
IL233934B (en) Antibodies to cd47, preparations containing them and their uses
EP3003390A4 (en) Anti-c10orf54 antibodies and uses thereof
EP2920742A4 (en) DEVICES, SYSTEMS AND METHOD FOR REINFORCING VISUAL ATTRIBUTES
IL254416A0 (en) Anti-asic1 antibodies and their uses
HK1206367A1 (zh) 中和 的抗體及其用途
EP2969719A4 (en) Three-wheeled vehicle
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL244043B (en) Antibodies against CSF-1r and their use.
HK1205523A1 (zh) 抗-大-內皮素- 抗體及其用途
EP2927080A4 (en) VEHICLE ACCELERATION SUPPRESSION DEVICE AND VEHICLE ACCELERATION SUPPRESSION METHOD
EP2822201A4 (en) COMMUNICATION SYSTEM, COMMUNICATION DEVICE, POWER SUPPLY DEVICE AND VEHICLE
PL2650310T3 (pl) Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
EP3041826A4 (en) Triazolone compounds and uses thereof
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof
EP3003298A4 (en) Anti-fibrogenic compounds, methods and uses thereof
EP2924265A4 (en) MOTOR-MOUNTED CONTROL DEVICE AND VEHICLE
AU2012904723A0 (en) Free Parking iPhone App.
AU2012902128A0 (en) Improved Objects.
AU2013904834A0 (en) Improved bicycle carrier for vehicles.